Abstract: Use of at least one polymer or one biopolymer called HBGFPP, specifically protecting the growth factors of FGFs and beta TGFs families from tryptic degradation in the manufacture of a drug for the treatment of lesions of the nervous system.

Abstract: A pharmaceutical composition for stimulating production of cytokines of inflammation including a peptide corresponding to formula (I) below:

Abstract: A process for detecting B lymphocytes including contacting a blood sample from a subject, or a fraction of the blood sample, with HARP polypeptide, a fragment or a derivative thereof, and detecting binding to the surface of B lymphocytes by polypeptide HARP, a fragment or a derivative thereof.

Abstract: Use of at least one polymer or one biopolymer called HBGFPP, specifically protecting the growth factors of FGFs and beta TGFs families from tryptic degradation in the manufacture of a drug for the treatment of lesions of the nervous system.

Abstract: A biocompatible polymer constituted by a sequence of identical or different components of the general formula (I): AaXxYy, in which A represents a monomer, X represents a carboxyl group fixed on a monomer A, Y represents a sulfate or sulfonate group fixed on a monomer A; a represents the number of monomers A, x represents the substitution rate of the set of monomers A by the groups X, y represents the substitution rate of the set of monomers A by the groups Y. The invention also pertains to the pharmaceutical or diagnostic compositions containing at least one polymer of general formula (I).

Abstract: Novel peptides having a SEQ ID No. 2 and SEQ ID No. 4 which peptides possess mitogenic properties.

Abstract: Use of at least one polymer or one biopolymer, called HBGFPP, specifically protecting the growth factors of the FGF and beta TGF families from tryptic degradation in the manufacture of a drug for the treatment of muscular tissues.

Abstract: Use of at least one polymer or one biopolymer, called HBGFPPs, specifically protecting the growth factors of families of FGFs and beta TGFs from tryptic degradation and not significantly inhibiting coagulation, in the manufacture of a drug for the treatment of lesions of the digestive tract and of primary or secondary derived tissues of the endoderm and the mesoderm.

Abstract: Compositions useful for regenerating cells and tissues comprise at least one functionalized dextran which has been substituted with carboxymethyl, benzylamide, or benzylamide sulfonate. These dextrans can be used alone or in combination with acid or basic fibroblast growth factors to enhance tissue or cell regeneration. Additionally, these dextrans enhance the stability of acid or basic fibroblast growth factors.

Abstract: A process for stimulating the growth of epidermis cells.The epidermis cells are contacted with an aqueous saline extract (RE) of ocular tissues. The process is especially applied for human epidermis cells.Application to the study of chromosomes of the human epidermis cell, particularly for the detection of natural or induced chromosome anomalies, and to the production of grafts, and especially autografts, usable on man, for example in the treatment of burns, cosmetic and diagnostic products.

Abstract: A process for stimulating the growth of human epidermal cells, applications of said process and products applying the said process.A process for stimulating the growth of epidermis cells.The epidermis cells are contacted with an aqueous saline extract (RE) of ocular tissues. The process is especially applied for human epidermis cells.Application to the study of chromosomes of the human epidermis cell, particularly for the detection of natural or induced chromosome anomalies, and to the production of grafts, and especially autografts, usable on man, for example in the treatment of burns, cosmetic and diagnostic products.

Abstract: A composition and a method for regenerating wounded or damaged corneal epelium are described. The composition comprises an aqueous solution containing an effective amount of ocular extract RE. The RE is extracted from eye tissues, such as choroid, iris and vitreous as well as aqueous humor. The active extract is obtained by the treatment of bovine ocular tissues with a buffered aqueous saline solution at pH of about 7.2. For ophthalmological use, the RE extract is purified by precipitation with acetic acid and dialyzed against physiologic saline NaCl solution. Such a composition is shown to increase significantly the rate of healing of wounded corneal epithelium.